An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)

Clinical Rheumatology

Volumn 29, Issue 10, 2010, Pages 1169-1173

  Jung, Norma ^a   Hellmann, Matthias ^a   Hoheisel, Reimund ^a   Lehmann, Clara ^a   Haase, Ingo ^a   Perniok, Andreas ^a   Hallek, Michael ^a   Rubbert, Andrea ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Anakinra; Efficacy; MTX pretreatment; Psoriatic arthritis; Safety

Indexed keywords

ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; QUESTIONNAIRE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952113703     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-010-1504-5     Document Type: Article

References (25)

1. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361(5):496-509
2. Gladman DD et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14-ii17
3. Ritchlin CT et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387-1394
4. Gottlieb A et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58(5):851-864
5. Furst DE et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66(Suppl 3):iii2-iii22
6. Mease PJ, Antoni CE (2005) Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 64(Suppl 2):ii78-ii82
7. Cohen S et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614-624
8. Pascual V et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479-1486
9. Fitzgerald AA et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52 (6):1794-1803
10. Botsios C et al (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149(4):284-286
11. Shinkai K, McCalmont TH, Leslie KS (2008) Cryopyrinassociated periodic syndromes and autoinflammation. Clin Exp Dermatol 33(1):1-9
12. de Koning HD et al (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37(3):137-148
13. Furlan A et al (2008) Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 75(3):366-367
14. Kalliolias GD, Liossis SN (2008) The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17(3):349-359
15. Gibbs A et al (2005) Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study. Arthritis Res Ther 7(Suppl 1):P68
16. Konttinen L et al (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25(6):882-884
17. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55-78
18. Mease PJ et al (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii49-ii54
19. Felson DT et al (1995) American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727-735
20. Fredriksson T, Pettersson U (1978) Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157(4):238-244
21. Hollis S, Campbell F (1999) What is meant by intention to treat analysiš Survey of published randomised controlled trials. Bmj 319(7211):670-674
22. Burger D et al (2006) Is IL-1 a good therapeutic target in the treatment of arthritiš Best Pract Res Clin Rheumatol 20(5):879-896
23. Dinarello CA (2005) The many worlds of reducing interleukin-1. Arthritis Rheum 52(7):1960-1967
24. Fleischmann RM et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65 (8):1006-1012
25. Fleischmann RM (2003) Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 42 (Suppl 2):ii29-ii35